A NEW ENZYMATIC TEST FOR THEOPHYLLINE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$458,101.00
Award Year:
1991
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
7864
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Gds Technology Inc.
25235 Leer Dr, Elkhart, IN, 46514
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
THEOPHYLLINE IS A DRUG CURRENTLY USED BY MOST ASTHMATIC/ALLERGIC ADULTS AND CHILDREN, CONSTITUTING OVER SIX MILLION PATIENTS. THERAPY REQUIRES FREQUENT MONITORING OF THEOPHYLLINE LEVELS IN BLOOD AS IT CAUSES TOXICITY AT CONCENTRATIONS HIGHER THAN 20MG/L AND IS INEFFECTIVE AT LOWER THAN 10 MG/L. CURRENT TESTING IS DONE IN HOSPITAL/COMMERCIAL LABORATORIES AT A COST OF $27.00 PER TEST TO MEDICARE/MEDICAID. THERE IS GREAT NEED FOR A COST EFFECTIVE, EASY TO PERFORM TEST FOR THEOPHYLLINE SO THAT PHYSICIANS, IN THEIR OFFICES, OR PATIENTS CAN QUICKLY MONITOR THIS DRUG BY USING A DROP OF WHOLE BLOOD FROM A FINGER TIP. CURRENT TESTS FOR THEOPHYLLINE USE ANTIGEN-ANTIBODY TECHNOLOGY AND ARE CUMBERSOME AND EXPENSIVE. ALTERNATIVELY,GDS TECHNOLOGY'S DISCOVERY OF A NEW ENZYME, NAMELY THEOPHYLLINE OXIDASE, WHICH SELECTIVELY OXIDIZES THEOPHYLLINE COULD ENABLE THE DEVELOPMENT OF A SIMPLE, CONVENIENT, AND SPECIFIC ENZYMATIC TEST. THIS PROPOSAL (PHASE I) FOCUSES ON INITIAL FEASIBILITY STUDIES AND WILL INCLUDE STUDYING THE PROPERTIES OF THIS ENZYME TO ESTABLISH ITS SUITABILITY FOR A COMMERCIAL TEST. THE GOAL OF PHASE II WILL BE THE DEVELOPMENT OF A CONVENIENT ENZYMATIC DRY CHEMISTRY TEST FOR THEOPHYLLINE WHICH WILL COST $1.00-2.00 AND THUS WILL GREATLY REDUCE HEALTH CARE COST.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government